company background image
2390 logo

Guizhou Xinbang Pharmaceutical SZSE:002390 Stock Report

Last Price

CN¥3.80

Market Cap

CN¥7.3b

7D

-5.5%

1Y

-23.7%

Updated

25 Mar, 2024

Data

Company Financials

Guizhou Xinbang Pharmaceutical Co., Ltd.

SZSE:002390 Stock Report

Market Cap: CN¥7.3b

2390 Stock Overview

Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally.

2390 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends4/6

Guizhou Xinbang Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guizhou Xinbang Pharmaceutical
Historical stock prices
Current Share PriceCN¥3.80
52 Week HighCN¥5.25
52 Week LowCN¥3.18
Beta0.50
1 Month Change-3.55%
3 Month Change-13.83%
1 Year Change-23.69%
3 Year Change-56.27%
5 Year Change-36.77%
Change since IPO-27.78%

Recent News & Updates

Recent updates

Shareholder Returns

2390CN PharmaceuticalsCN Market
7D-5.5%-1.6%-0.03%
1Y-23.7%-8.6%-14.2%

Return vs Industry: 002390 underperformed the CN Pharmaceuticals industry which returned -8.6% over the past year.

Return vs Market: 002390 underperformed the CN Market which returned -14.2% over the past year.

Price Volatility

Is 2390's price volatile compared to industry and market?
2390 volatility
2390 Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement6.9%
Market Average Movement8.1%
10% most volatile stocks in CN Market11.3%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 002390 has not had significant price volatility in the past 3 months.

Volatility Over Time: 002390's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19955,408Lingzhong Konghttps://www.xinbang.com

Guizhou Xinbang Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells Chinese herbal medicines and other pharmaceutical products in China and internationally. The company offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medicine, gynecological treatment, and anti-infective drugs. It also operates in medical services; and pharmaceutical circulation business.

Guizhou Xinbang Pharmaceutical Co., Ltd. Fundamentals Summary

How do Guizhou Xinbang Pharmaceutical's earnings and revenue compare to its market cap?
2390 fundamental statistics
Market capCN¥7.33b
Earnings (TTM)CN¥230.02m
Revenue (TTM)CN¥6.49b

31.8x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2390 income statement (TTM)
RevenueCN¥6.49b
Cost of RevenueCN¥5.25b
Gross ProfitCN¥1.23b
Other ExpensesCN¥1.00b
EarningsCN¥230.02m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 16, 2024

Earnings per share (EPS)0.12
Gross Margin19.00%
Net Profit Margin3.55%
Debt/Equity Ratio15.8%

How did 2390 perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

49%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.